diltiazem has been researched along with diclofenac in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.13) | 18.2507 |
| 2000's | 17 (43.59) | 29.6817 |
| 2010's | 19 (48.72) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Kanebratt, KP; Sjögren, E; Svanberg, P | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ayuga, TD; Balogun, EO; Dardonville, C; de Koning, HP; Donachie, A; Ebiloma, GU; Gil, LA; Harada, S; Herraiz, T; Inaoka, DK; Kaiser, M; Kita, K; Shiba, T | 1 |
| Bajusz, D; Balogh, GT; Dargó, G; Müller, J; Simon, K | 1 |
| Estler, CJ; Lepper, H; Schmitz, G | 1 |
| Belmonte, C; Chen, X; Gallar, J | 1 |
| Ibrahim, HG; Kakish, HF; Najib, NM; Tashtoush, B | 1 |
| Al-Ghazawi, M; Bani-Jaber, A | 1 |
| Kosmidis, K; Macheras, P; Papadopoulou, V; Vlachou, M | 1 |
| Cakalağaoğlu, F; Gürsoy, A; Okar, I; Sipahigil, O | 1 |
| Chanda, E; Datta, BK; Haider, SS; Quadir, MA; Reza, MD | 1 |
| Krejcová, K; Polásek, E; Prokopová, A; Rabisková, M; Tomásek, V; Vetchý, D | 1 |
| Corish, J; Corrigan, OI; Fitzpatrick, D; Nolan, LM | 1 |
| Barabde, UV; Joshi, SB; Morkhade, DM; Nande, VS; Patil, AT | 1 |
| Hosoi, Y; Kanamaru, T; Konno, T; Nakagami, H; Tajiri, S; Yada, S; Yoshida, K | 1 |
| Jachowicz, R; Krupa, A; Pędzich, Z; Wodnicka, K | 1 |
| Aykur, M; Güney, M; Kaplan, Ö; Nazıroğlu, M | 1 |
| Kelemen, A; Kónya, Z; Pintye-Hódi, K; Regdon, G; Sipos, B; Sovány, T | 1 |
| Chiang, W; Li, ML; Lin, JH; Liu, YT; Yao, HT | 1 |
| Akar, EA; Aker, FV; Emon, ST; Engin, T; Erdogan, B; Is, M; Sayman, E; Somay, H | 1 |
2 review(s) available for diltiazem and diclofenac
| Article | Year |
|---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
37 other study(ies) available for diltiazem and diclofenac
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
Topics: Chromatography, Liquid; Cytochrome P-450 Enzyme System; Humans; Kinetics; Microsomes, Liver; Research Design; Tandem Mass Spectrometry | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Inhibition of trypanosome alternative oxidase without its N-terminal mitochondrial targeting signal (ΔMTS-TAO) by cationic and non-cationic 4-hydroxybenzoate and 4-alkoxybenzaldehyde derivatives active against T. brucei and T. congolense.
Topics: Benzaldehydes; Cations; Dose-Response Relationship, Drug; Mitochondrial Proteins; Molecular Structure; Oxidoreductases; Parabens; Parasitic Sensitivity Tests; Plant Proteins; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma; Trypanosoma brucei brucei; Trypanosoma congolense | 2018 |
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
Topics: Binding Sites; Chemistry, Pharmaceutical; Drug Design; Humans; Hydrogen-Ion Concentration; Molecular Docking Simulation; Pharmaceutical Preparations; Protein Binding; Serum Albumin, Human; Spectrophotometry, Ultraviolet; Titrimetry | 2020 |
Failure of calcium antagonistic agents to prevent hepatotoxicity induced by diclofenac.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Cell Survival; Cells, Cultured; Chelating Agents; Diclofenac; Diltiazem; Dose-Response Relationship, Drug; Drug Interactions; Liver; Male; Rats; Rats, Wistar; Verapamil | 1995 |
Reduction by antiinflammatory drugs of the response of corneal sensory nerve fibers to chemical irritation.
Topics: Acetic Acid; Analgesia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Carbon Dioxide; Cats; Cornea; Cyclooxygenase Inhibitors; Diclofenac; Diltiazem; Electrophysiology; Female; Flurbiprofen; Indomethacin; Male; Nerve Fibers; Nociceptors; Pain; Trigeminal Nerve | 1997 |
A novel approach for the preparation of highly loaded polymeric controlled release dosage forms of diltiazem HCl and diclofenac sodium.
Topics: Delayed-Action Preparations; Diclofenac; Diltiazem; Dosage Forms; Polymers; Technology, Pharmaceutical | 2002 |
Sustained release characteristics of tablets prepared with mixed matrix of sodium carrageenan and chitosan: effect of polymer weight ratio, dissolution medium, and drug type.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Biocompatible Materials; Carrageenan; Chemistry, Pharmaceutical; Chitosan; Delayed-Action Preparations; Diclofenac; Diltiazem; Hydrogen-Ion Concentration; Tablets | 2005 |
On the use of the Weibull function for the discernment of drug release mechanisms.
Topics: Delayed-Action Preparations; Diclofenac; Diffusion; Diltiazem; Hypromellose Derivatives; Kinetics; Methylcellulose; Models, Chemical; Polymers; Solubility; Tablets | 2006 |
Release behaviour and biocompatibility of drug-loaded pH sensitive particles.
Topics: Administration, Oral; Animals; Diclofenac; Diltiazem; Drug Carriers; Drug Stability; Gap Junctions; Hydrogen-Ion Concentration; Ileum; Isoniazid; Microscopy, Electron, Transmission; Molecular Weight; Particle Size; Polyethylene Glycols; Polymethacrylic Acids; Rats; Rats, Wistar; Solubility; Time Factors | 2006 |
Evaluation of ethylcellulose as matrices for controlled release drug delivery.
Topics: Cellulose; Compressive Strength; Delayed-Action Preparations; Diclofenac; Diltiazem; Drug Carriers; Hydrogen-Ion Concentration; Kinetics; Solubility; Tablets; Technology, Pharmaceutical; Theophylline; Time Factors | 2005 |
The influence of drug solubility and particle size on the pellet formulation in a rotoprocessor.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Bronchodilator Agents; Calcium Channel Blockers; Cellulose; Chemistry, Pharmaceutical; Diclofenac; Diltiazem; Drug Compounding; Excipients; Lactase; Particle Size; Solubility; Theophylline; Water | 2006 |
Combined effects of iontophoretic and chemical enhancement on drug delivery. II. Transport across human and murine skin.
Topics: Administration, Cutaneous; Albuterol; Animals; Chemistry, Pharmaceutical; Diclofenac; Diffusion; Diffusion Chambers, Culture; Diltiazem; Drug Compounding; Drug Delivery Systems; Fatty Acids; Gels; Humans; Iontophoresis; Kinetics; Lauric Acids; Liquid Crystals; Mice; Mice, Hairless; Models, Biological; Nicotine; Oleic Acid; Permeability; Pharmaceutical Preparations; Pharmaceutical Vehicles; Skin; Skin Absorption; Stearic Acids | 2007 |
PEGylated rosin derivatives: novel microencapsulating materials for sustained drug delivery.
Topics: Delayed-Action Preparations; Diclofenac; Diltiazem; Microspheres; Particle Size; Polyethylene Glycols; Resins, Plant; Solubility; Spectroscopy, Fourier Transform Infrared; Surface Properties; Viscosity | 2007 |
The relationship between the drug concentration profiles in plasma and the drug doses in the colon.
Topics: Administration, Oral; Animals; Anti-Allergic Agents; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Area Under Curve; Biological Availability; Colon; Delayed-Action Preparations; Diclofenac; Diltiazem; Dogs; Dose-Response Relationship, Drug; Hypoglycemic Agents; Metformin; Muscarinic Agonists; Quinuclidines; Terfenadine; Thiophenes; Verapamil | 2010 |
The influence of the API properties on the ODTs manufacturing from co-processed excipient systems.
Topics: Administration, Oral; Chemistry, Pharmaceutical; Diclofenac; Diltiazem; Drug Compounding; Excipients; Hardness; Ibuprofen; Particle Size; Pressure; Solubility; Tablets; Technology, Pharmaceutical | 2012 |
Non-steroidal anti-inflammatory drug modulates oxidative stress and calcium ion levels in the neutrophils of patients with primary dysmenorrhea.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Boron Compounds; Calcium; Calcium Channels; Cells, Cultured; Diclofenac; Diltiazem; Dysmenorrhea; Female; Glutathione Peroxidase; Humans; Lipid Peroxidation; Neutrophil Activation; Neutrophils; Oxidative Stress; Verapamil; Young Adult | 2013 |
Physicochemical characterisation and investigation of the bonding mechanisms of API-titanate nanotube composites as new drug carrier systems.
Topics: Atenolol; Calorimetry, Differential Scanning; Diclofenac; Diltiazem; Drug Carriers; Drug Liberation; Hydrochlorothiazide; Microscopy, Electron, Scanning; Nanotubes; Solubility; Spectroscopy, Fourier Transform Infrared; Surface Properties; Thermogravimetry; Titanium | 2017 |
Food-Drug Interaction between the Adlay Bran Oil and Drugs in Rats.
Topics: Administration, Intravenous; Administration, Oral; Animals; Capsaicin; Chlorzoxazone; Cytochrome P-450 Enzyme System; Dextromethorphan; Diclofenac; Diltiazem; Food-Drug Interactions; Intestinal Absorption; Intestines; Liver; Male; Plant Oils; Rats, Sprague-Dawley; Risk Assessment; Theophylline | 2019 |
Preventative effect of diclofenac sodium and/or diltiazem in rats with epidural fibrosis.
Topics: Animals; Diclofenac; Diltiazem; Epidural Space; Fibrosis; Laminectomy; Rats | 2019 |